Presentations & Publications
IpY.20, a first-in-class inhibitor of p27Kip1, inhibits CDK4/6 and CDK2 to kill tumor cell
Targeting p27Kip1 to inhibit CDK4/6/2 as a novel therapeutic strategy to treat pancreatic ductal adenocarcinoma
NP-ALT, a liposomal:peptide drug, blocks p27Kip1 phosphorylation to cause cell death in CDK4i-resistant breast cancer
Developing IpY: A novel inhibitor for the treatment of ER+ CDK4i-resistant breast cancer
Concarlo in the News
LIPOSOMAL PEPTIDE THERAPEUTICS – Revolutionizing Oncology: Unleashing Innovative Strategies to Tackle Challenging, High-Value Drug Targets
CDK Inhibitors: Why Women – and Men – Should Know About This ‘New Era’ Of Cancer Treatment
Breast Cancer Deserves More Than A Month
Life Sciences Review special edition on BioTech Startup 2022
Webinars & Talks
Heroes of Healthcare – Episode 50: Shutting the Door on Cancer Cells
LabOps: Changing Outcomes for Drug-Resistant Patients with Stacy Blain, Founder, and CSO at Concarlo Therapeutics
Case Study: Developing liposomal formulation of a novel 91-mer synthetic peptide for treatment of ER+ CDK4i resistant Breast Cancer
The Cancer Moonshot: A 5 Year Review
Awards
“The reward for work well done is the opportunity to do more”
—Jonas Salk
The 50 Most admired companies: CIO Bio
Top 100 entreprenuers: Alumni List
Top Biotech Startup 2022
Awarded by: Life Sciences Review
